November 01, 2026

To,
The BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001
Scrip Code: 540737

Dear Sir/Ma'am,

Sub: Press Release

With reference to the captioned subject, we enclose herewith the Press Release with respect to Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026.

Kindly take the same on your record.

Thanking You,

Yours faithfully,

For Shree Ganesh Remedies Limited

AKANKSHA
Digitally signed by AKANKSHA
Date: 2026.11.01 19:02:10 +05'30'

Akanksha
Company Secretary and Compliance Officer

Enc. a/a

SHREE GANESH REMEDIES LIMITED REPORTS Q2 & H1FY27 RESULTS

Ankleshwar, October 31st, 2026: Shree Ganesh Remedies Limited, one of the fastest growing CMO & CDMO based in India for Pharmaceutical Intermediates & Fine Chemicals, announced its financial results for Q2 & H1FY27.

Financial Highlights for Quarter Ended September 30th, 2026:

(₹ In crore & %)

REVENUE	EBITDA	PAT	EBITDA MARGINS
23.29 Cr.	**3.94 Cr.**	**1.63 Cr.**	**16.9%**
ⓓ **-23% YoY**	ⓓ **-59% YoY**	ⓓ **-67% YoY**	ⓓ **-1,483 BPS YoY**
13.61 Cr. Revenue from Pharma Intermediates in Q2FY27	**9.37 Cr.** Revenue from Speciality Chemicals in Q2FY27	**11.71 Cr.** Revenue from Exports in Q2FY27	**11.28 Cr.** Revenue from Domestic Sales in Q2FY27

Financial Highlights for Half Year Ended September 30th, 2026:

(₹ In crore & %)

REVENUE	EBITDA	PAT	EBITDA MARGINS
37.65 Cr.	**7.29 Cr.**	**2.75 Cr.**	**19.4%**
ⓓ **-32% YoY**	ⓓ **-57% YoY**	ⓓ **-67% YoY**	ⓓ **-1,141 BPS YoY**
25.10 Cr. Revenue from Pharma Intermediates in H1FY27	**12.25 Cr.** Revenue from Speciality Chemicals in H1FY27	**20.35 Cr.** Revenue from Exports in H1FY27	**17.00 Cr.** Revenue from Domestic Sales in H1FY27

Commenting on the results, Mr. Gunjan Kothia, Promoter said:

FY27 began on a challenging note for the Company. Subdued demand from Europe and a difficult operating environment weighed on our first-quarter performance. Over the past three months, we have worked steadily through these challenges, and this is reflected in an improved performance in Q2FY27.

Much of this improvement has come from our core pharmaceutical intermediates business, where we sharpened our focus on the domestic market to make up for softer exports. Alongside this, we have begun to see improved traction from our European customers, which gives us confidence that the core business will recover to its earlier levels over the next few quarters. We have also broadened our portfolio during the quarter by commencing commercial production of two new pharmaceutical intermediates, one for anti-diabetic and one for cardiovascular applications. Both have received an encouraging response in the domestic market, and we plan to take them to export markets in the coming quarters.

While volumes are on the path to recovery, they remain below earlier levels, and this has put some pressure on our margins. Raw material prices added to this pressure, rising significantly and staying volatile through the quarter. We expect input costs to ease as geopolitical conditions stabilise, and margins to normalise as our sales return to earlier levels. Throughout, we remain focused on healthy profitability, including on the new products we are developing.

As we work towards this recovery, we continue to build the businesses that will drive our next phase of growth. Our CRAMS business has made strong progress during the quarter. On our specialty chemicals project for South-East Asian markets, we have successfully completed the pilot trials, and the batches are now undergoing stability testing, with commercial supplies expected from Q1FY28. A second specialty chemicals product for the same region has cleared laboratory trials and moved to the pilot stage. In Europe, we are making positive progress on two molecules for pharmaceutical and agrochemical applications. To support this pipeline, construction of Block 7A is now complete and trials have begun.

This year has brought its own set of challenges, and we have responded by strengthening our domestic presence, adding to our product portfolio and advancing our CRAMS pipeline. With the core business recovering, new products gaining traction and new capacity coming online, we look forward to a stronger performance in the periods ahead.

Financial Highlights:

PARTICULARS (₹ IN CRORES)	**Q2FY26**	**Q1FY27**	**Q2FY27**	**YoY Change**	**QoQ Change**	**H1FY26**	**H1FY27**	**YoY Change**
Revenue from Operations	**30.32**	**14.36**	**23.29**	**-23%**	**62%**	**54.98**	**37.65**	**-32%**
Total Income	31.00	15.30	24.70	-20%	61%	56.33	40.00	-29%
Operating Expenses	20.70	11.01	19.36	-6%	76%	38.07	30.37	-20%
EBITDA (Excluding OI & EI)	**9.62**	**3.35**	**3.94**	**-59%**	**17%**	**16.92**	**7.29**	**-57%**
EBITDA %	**31.7%**	**23.3%**	**16.9%**	**-1,483 bps**	**-644 bps**	**30.8%**	**19.4%**	**-1141 bps**
Finance Cost	1.01	0.32	0.58	-43%	80%	1.95	0.89	-54%
Depreciation & Ammortization	2.59	2.44	2.50	-3%	3%	5.01	4.94	-1%
PBT	6.71	1.53	2.26	-66%	48%	11.31	3.79	-66%
PAT	**4.96**	**1.12**	**1.63**	**-67%**	**46%**	**8.41**	**2.75**	**-67%**
EPS (₹)	3.86	0.87	1.28	-67%	47%	6.55	2.15	-67%

About Shree Ganesh Remedies Limited: (SGRL)

Shree Ganesh Remedies Limited is a leading player in the chemical manufacturing industry, specialising in pharmaceutical intermediates and specialty chemicals. With over 20 years of excellence, the company is renowned for its unparalleled expertise in advanced chemical synthesis and complex chemical reactions. Strategically expanding its operations, Shree Ganesh Remedies is focused on innovation through strategic R&D investments and state-of-the-art infrastructure. The company serves over 20 countries, including key markets in the EU and the US, offering tailored solutions to global industry leaders. Committed to sustainable practices, Shree Ganesh Remedies holds multiple accreditations, including ISO certifications and EcoVadis Bronze. With ongoing expansions at its Ankleshwar and Dahej sites and a strategic shift towards complex niche specialty chemicals, the company is well-positioned for future growth and continues to deliver high-quality, custom manufacturing solutions to its clients.

Contact us:

Akanksha Choudhary
Company Secretary
Shree Ganesh Remedies Limited
Email: investors@ganeshremedies.com

Abhishek Mehra
Investor Relations Advisors
TIL Advisors Private Limited
Email: abhishek@theinvestmentlab.in
Mobile No.: +91 95588 14500

Certain statements in this document that are not historical facts are forward looking statements. Such forward looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward- looking statements. Shree Ganesh Remedies Limited will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.